Semler Scientific Inc's Stock Falls 5.77% on July 15 Amidst Analyst Predictions of a 129.94% Upside.

Shares of Semler Scientific Inc (SMLR) fell 5.77% on Jul 15, reaching an intraday low of $40.73 and recovering to $42.62. Trading volume was 571,778 shares, 43.8% of the average daily volume. Analysts forecast an average target price of $98.00, implying an upside of 129.94% from the current price. The average brokerage recommendation is 2.0, indicating an "Outperform" status.

Semler Scientific Inc (SMLR) experienced a significant drop in its share price on July 15, 2025, with shares falling 5.77% to reach an intraday low of $40.73 before recovering to $42.62. The trading volume was notably high, at 571,778 shares, which was 43.8% of the average daily volume [1].

The decline in Semler Scientific's stock price can be attributed to ongoing regulatory investigations and potential legal liabilities. In February 2025, the company disclosed that it had received an initial civil investigative demand from the U.S. Department of Justice (DOJ) regarding reimbursement claims related to its QuantaFlo device. Subsequent demands for information were received in 2019, 2021, and 2023, and the company participated in settlement discussions with the DOJ in February 2025, which were unsuccessful. The company has warned that there is a risk of the DOJ filing a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages [1].

Despite the regulatory headwinds, analysts remain optimistic about Semler Scientific's prospects. According to MarketBeat, the consensus analyst rating for Semler Scientific is "Buy," with an average price target of $98.00. This implies an upside of 129.94% from the current price of $42.62. The average brokerage recommendation is 2.0, indicating an "Outperform" status [2].

Analysts at Lake Street Capital have been particularly positive about Semler Scientific, rating it more favorably than its competitors in the "medical" sector. The consensus rating for Semler Scientific is "Buy," while the average consensus rating for "medical" companies is "Moderate Buy" [2].

In conclusion, while Semler Scientific faces regulatory challenges, analysts remain bullish on the company's long-term prospects. Investors should closely monitor the company's legal developments and analyst recommendations to make informed decisions.

References:
[1] https://www.globenewswire.com/news-release/2025/07/14/3115243/0/en/Bragar-Eagel-Squire-P-C-Continues-Investigations-on-Behalf-of-SelectQuote-Cleveland-Cliffs-EchoStar-and-Semler-and-Encourages-Investors-to-Contact-the-Firm.html
[2] https://www.marketbeat.com/stocks/NASDAQ/SMLR/forecast/